166 related articles for article (PubMed ID: 38280761)
21. [Microbiological diagnosis of bronchopulmonary colonization-infection in cystic fibrosis].
Oliver A; Alarcón T; Caballero E; Cantón R
Enferm Infecc Microbiol Clin; 2009 Feb; 27(2):89-104. PubMed ID: 19232782
[TBL] [Abstract][Full Text] [Related]
22. [Chinese experts consensus statement: diagnosis and treatment of cystic fibrosis (2023)].
; ;
Zhonghua Jie He He Hu Xi Za Zhi; 2023 Apr; 46(4):352-372. PubMed ID: 36990700
[TBL] [Abstract][Full Text] [Related]
23. Rationale and Prospects of Targeting Bacterial Two-component Systems for Antibacterial Treatment of Cystic Fibrosis Patients.
Velikova N; Wells JM
Curr Drug Targets; 2017; 18(6):687-695. PubMed ID: 26853320
[TBL] [Abstract][Full Text] [Related]
24. Respiratory bacterial infections in cystic fibrosis.
Ciofu O; Hansen CR; Høiby N
Curr Opin Pulm Med; 2013 May; 19(3):251-8. PubMed ID: 23449384
[TBL] [Abstract][Full Text] [Related]
25. Use of random amplified polymorphic DNA PCR to examine epidemiology of Stenotrophomonas maltophilia and Achromobacter (Alcaligenes) xylosoxidans from patients with cystic fibrosis.
Krzewinski JW; Nguyen CD; Foster JM; Burns JL
J Clin Microbiol; 2001 Oct; 39(10):3597-602. PubMed ID: 11574579
[TBL] [Abstract][Full Text] [Related]
26. Newer antibacterial agents and their potential role in cystic fibrosis pulmonary exacerbation management.
Parkins MD; Elborn JS
J Antimicrob Chemother; 2010 Sep; 65(9):1853-61. PubMed ID: 20605846
[TBL] [Abstract][Full Text] [Related]
27. Update on antibiotics for infection control in cystic fibrosis.
Kirkby S; Novak K; McCoy K
Expert Rev Anti Infect Ther; 2009 Oct; 7(8):967-80. PubMed ID: 19803706
[TBL] [Abstract][Full Text] [Related]
28. "Pathogen Eradication" and "Emerging Pathogens": Difficult Definitions in Cystic Fibrosis.
Gilligan PH; Downey DG; Elborn JS; Flume PA; Funk S; Gilpin D; Kidd TJ; McCaughan J; Millar BC; Murphy PG; Rendall JC; Tunney MM; Moore JE
J Clin Microbiol; 2018 Sep; 56(9):. PubMed ID: 29875191
[TBL] [Abstract][Full Text] [Related]
29. Biofilm compared to conventional antimicrobial susceptibility of Stenotrophomonas maltophilia Isolates from cystic fibrosis patients.
Wu K; Yau YC; Matukas L; Waters V
Antimicrob Agents Chemother; 2013 Mar; 57(3):1546-8. PubMed ID: 23295930
[TBL] [Abstract][Full Text] [Related]
30. Antibiotic management of methicillin-resistant Staphylococcus aureus--associated acute pulmonary exacerbations in cystic fibrosis.
Fusco NM; Toussaint KA; Prescott WA
Ann Pharmacother; 2015 Apr; 49(4):458-68. PubMed ID: 25583881
[TBL] [Abstract][Full Text] [Related]
31. Trends in ceftazidime-avibactam activity against multidrug-resistant organisms recovered from respiratory samples of cystic fibrosis patients.
Farfour E; Trochu E; Devin C; Cardot Martin E; Limousin L; Roux A; Picard C; Jolly E; Vasse M; Lesprit P
Transpl Infect Dis; 2018 Oct; 20(5):e12955. PubMed ID: 29896802
[No Abstract] [Full Text] [Related]
32. Current dilemmas in antimicrobial therapy in cystic fibrosis.
Jain K; Smyth AR
Expert Rev Respir Med; 2012 Aug; 6(4):407-22. PubMed ID: 22971066
[TBL] [Abstract][Full Text] [Related]
33. Synergistic activities of macrolide antibiotics against Pseudomonas aeruginosa, Burkholderia cepacia, Stenotrophomonas maltophilia, and Alcaligenes xylosoxidans isolated from patients with cystic fibrosis.
Saiman L; Chen Y; Gabriel PS; Knirsch C
Antimicrob Agents Chemother; 2002 Apr; 46(4):1105-7. PubMed ID: 11897598
[TBL] [Abstract][Full Text] [Related]
34. Does Cefiderocol Have a Potential Role in Cystic Fibrosis Pulmonary Exacerbation Management?
Gavioli EM; Guardado N; Haniff F; Deiab N; Vider E
Microb Drug Resist; 2021 Dec; 27(12):1726-1732. PubMed ID: 34077286
[TBL] [Abstract][Full Text] [Related]
35. In vitro activity of minocycline against respiratory pathogens from patients with cystic fibrosis.
Kurlandsky LE; Fader RC
Pediatr Pulmonol; 2000 Mar; 29(3):210-2. PubMed ID: 10686042
[TBL] [Abstract][Full Text] [Related]
36. The Effects of Antibiotic Combination Treatments on Pseudomonas aeruginosa Tolerance Evolution and Coexistence with Stenotrophomonas maltophilia.
Law JP; Wood AJ; Friman VP
Microbiol Spectr; 2022 Dec; 10(6):e0184222. PubMed ID: 36453898
[TBL] [Abstract][Full Text] [Related]
37. Risk factors for emergence of Stenotrophomonas maltophilia in cystic fibrosis.
Talmaciu I; Varlotta L; Mortensen J; Schidlow DV
Pediatr Pulmonol; 2000 Jul; 30(1):10-5. PubMed ID: 10862157
[TBL] [Abstract][Full Text] [Related]
38. Changing Epidemiology of the Respiratory Bacteriology of Patients With Cystic Fibrosis.
Salsgiver EL; Fink AK; Knapp EA; LiPuma JJ; Olivier KN; Marshall BC; Saiman L
Chest; 2016 Feb; 149(2):390-400. PubMed ID: 26203598
[TBL] [Abstract][Full Text] [Related]
39. Improving outcomes of infections in cystic fibrosis in the era of CFTR modulator therapy.
Saiman L
Pediatr Pulmonol; 2019 Nov; 54 Suppl 3():S18-S26. PubMed ID: 31715086
[TBL] [Abstract][Full Text] [Related]
40. Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis.
Langton Hewer SC; Smyth AR
Cochrane Database Syst Rev; 2017 Apr; 4(4):CD004197. PubMed ID: 28440853
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
